Oruka Therapeutics, Inc.
91.50USD
-2.8100 (-2.98%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q3 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | 0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -50 | -36 | -34 | -34 | -28 | -25 | -29 | -21 |
| Net Income | -41 | -32 | -30 | -30 | -25 | -21 | -29 | -22 |
| EPS (Diluted) | — | — | — | — | $-0.46 | $-0.40 | $-1.46 | $-6.96 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)